

Jonathan W Goldman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4753679/publications.pdf>

Version: 2024-02-01

46
papers

3,916
citations

279798

23
h-index

289244

40
g-index

46
all docs

46
docs citations

46
times ranked

5986
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort. JCO Oncology Practice, 2022, 18, e484-e494.	2.9	3
2	Pozotinib in Non-HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. Journal of Clinical Oncology, 2022, 40, 710-718.	1.6	72
3	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clinical Cancer Research, 2022, 28, 2286-2296.	7.0	14
4	A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. JTO Clinical and Research Reports, 2022, 3, 100262.	1.1	7
5	A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib. Clinical Lung Cancer, 2022, 23, 300-310.	2.6	12
6	ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study. Clinical Cancer Research, 2022, 28, 2517-2526.	7.0	14
7	Facets of stigma, self-compassion, and health-related adjustment to lung cancer: A longitudinal study.. Health Psychology, 2022, 41, 301-310.	1.6	3
8	A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non-small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting.. Journal of Clinical Oncology, 2022, 40, 9038-9038.	1.6	1
9	Circulating tumor DNA (ctDNA) mutations associate with response in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib (TALA) and temozolomide (TMZ).. Journal of Clinical Oncology, 2022, 40, 8582-8582.	1.6	0
10	Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met-overexpressing (OE) advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, 9016-9016.	1.6	33
11	Adverse events self-reported by patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with durvalumab (D) plus platinum-etoposide (EP) or EP in the CASPIAN study.. Journal of Clinical Oncology, 2022, 40, 8571-8571.	1.6	0
12	Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.. Journal of Clinical Oncology, 2022, 40, 9008-9008.	1.6	24
13	Inter-reader reliability of immune-specific response criteria (irRECIST & iRECIST).. Journal of Clinical Oncology, 2022, 40, e21108-e21108.	1.6	0
14	Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, 9013-9013.	1.6	14
15	Immunogenicity and disease control induced by a multineoantigen vaccine (ADXS-503) in patients with metastatic non-small cell lung cancer who have progressed on pembrolizumab.. Journal of Clinical Oncology, 2022, 40, 9042-9042.	1.6	1
16	Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.. Journal of Clinical Oncology, 2022, 40, TPS9154-TPS9154.	1.6	0
17	A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 3630-3640.	7.0	11
18	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clinical Cancer Research, 2021, 27, 5781-5792.	7.0	30

#	ARTICLE	IF	CITATIONS
19	The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Review of Anticancer Therapy, 2021, 21, 1105-1124.	2.4	26
20	Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer. Clinical and Translational Science, 2021, 14, 664-670.	3.1	2
21	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discovery, 2020, 10, 40-53.	9.4	219
22	Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer, 2020, 149, 46-52.	2.0	28
23	Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. New England Journal of Medicine, 2020, 383, 825-835.	27.0	454
24	Targeted Therapy for Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 409-434.	2.1	11
25	Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, The, 2019, 394, 1929-1939.	13.7	1,274
26	Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story. Journal of Thoracic Oncology, 2019, 14, 160-162.	1.1	0
27	KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment. Translational Lung Cancer Research, 2019, 8, 706-709.	2.8	5
28	Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. Cancer Immunology Research, 2018, 6, 288-294.	3.4	70
29	Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401775163.	3.2	29
30	Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. Scientific Reports, 2018, 8, 2592.	3.3	81
31	Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Clinical Lung Cancer, 2018, 19, e19-e28.	2.6	17
32	nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC. Frontiers in Oncology, 2018, 8, 262.	2.8	9
33	A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment. Journal of Thoracic Oncology, 2018, 13, 1284-1293.	1.1	30
34	Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. Journal of Thoracic Oncology, 2018, 13, 1363-1372.	1.1	140
35	Phase I Trial of Intratumoral Injection of CCL21-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clinical Cancer Research, 2017, 23, 4556-4568.	7.0	149
36	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respiratory Medicine, 2017, 5, 891-902.	10.7	92

#	ARTICLE	IF	CITATIONS
37	A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1910-1919.	7.0	66
38	Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. <i>Oncologist</i> , 2016, 21, 1326-1336.	3.7	49
39	A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 604-613.	2.6	65
40	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016, 7, 11815.	12.8	520
41	Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2016, 17, 80-84.	2.6	45
42	MET-Mutated NSCLC with Major Response to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2015, 10, e33-e34.	1.1	53
43	High efficiency vortex trapping of circulating tumor cells. <i>Biomechanics</i> , 2015, 9, 064116.	2.4	60
44	A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. <i>BMC Cancer</i> , 2013, 13, 152.	2.6	99
45	Targeting MEK for the Treatment of Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, S377-S378.	1.1	10
46	Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) tyrosine kinase inhibitor, crizotinib, and the selective mTOR inhibitor, everolimus, in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, 111-119.	4.1	74